- Babesia canis infections in dogs in Germany – current overview, new findings and practical recommendations (as of July 2025)
- 1 | Introduction – why this update?
- 2 | Epidemiology in Germany – from hotspot to widespread problem
- 3 | Pathogenesis and immune response – what we will know in 2025
- 4 | Clinical picture – „typically atypical“
- 5 | Diagnostic Roadmap
- 6 | Therapy – state of the art
- 7 | Prevention – Keeping an eye on ticks and animals
- 8 | Public health context
- 9 | Outlook – what does the future hold?
- 10 | Conclusion
- 11 | FAQs – Frequently Asked Questions from Practice
- 12 | Summary
- 13 | Literature & Online Sources (Selection)
Babesia canis infections in dogs in Germany – current overview, new findings and practical recommendations (as of July 2025)
Summary for those in a hurry
Babesia canis infections now occur year-round in Germany – even in dogs that have not traveled abroad. Thanks to systematic tick surveillance, the meadow tick is Dermacentor reticulatus Now established in almost all German states. Early diagnosis (capillary blood smear + PCR) and consistent high-dose therapy with imidocarb dipropionate ensure a good prognosis. High antibody titers appear to protect against severe forms of the disease, while seronegative animals have a significantly higher risk of acute complications.
1 | Introduction – why this update?
Ten years ago, autochthonous cases of Babesia canis (Bc) in dogs is still a rarity in this country; today it is part of clinical routine in many regions. This update summarizes the current state of knowledge, expands the original case reports by Schäfer et al. (2022) with more recent epidemiological data (2023–2025), and derives clear recommendations for practitioners and owners.
2 | Epidemiology in Germany – from hotspot to widespread problem
- Year-round risk: Unlike before 2015, veterinary offices and university research groups are now observing evidence of Bacillus cereus in all seasons. ^[1]
- Vector propagation: The „classic“ BC risk areas – Berlin-Brandenburg, Rhine-Main, Saarland, Saxony/Saxony-Anhalt – have been joined since 2023 by a mosaic of new positive reports from Lower Saxony, Schleswig-Holstein and northern Bavaria. ^[2]
- Climate and land use factors: Milder winters, wildlife migrations (especially deer and foxes), and fallow land promote the survival of D. reticulatus. A multicenter GIS analysis (University of Leipzig 2024) showed a significant correlation between tick densities and areas with > 50% permanent grassland. ^[3]
3 | Pathogenesis and immune response – what we will know in 2025
After an incubation period of 5 to 28 days, the sporozoites invade erythrocytes and multiply as merozoites. The extent of intravascular hemolysis depends strongly on the cellular immune response. Canine studies from Giessen (2024) showed that:
- Titer threshold ≈ 80 IFA units often involves purely subclinical courses.
- Seronegative animals show up to a 6 times higher probability of shock events. ^[4]
4 | Clinical picture – „typically atypical“
| Leading symptom | Frequency* | remark |
|---|---|---|
| lethargy | 91 % | often the first and only symptom in the early phase |
| Loss of appetite | 88 % | along with nausea/vomiting |
| Fever > 39.2 °C | 54 % | Severe cases may be afebrile or hypothermic |
| Thrombocytopenia | 85 % | in 49 % highly (< 50 G/l) |
| anemia | 79 % | usually mild, 10 % hemolytic crisis |
| Leukopenia | 50 % | va neutropen |
*Data source: multicenter retrospective study 2019–2024, n = 342 dogs.
Note: The classic "red urine flush" is now only observed in about one in ten patients. The absence of hemoglobinuria does not rule out Bc.
5 | Diagnostic Roadmap
- Capillary blood smear (e.g. ear vein blood) → rapid microscopic orientation (sensitivity 60–70 %).
- Real-Time PCR (EDTA blood) → Gold standard for species differentiation (B. canis, B. vogeli, B. gibsoni, B. vulpes).
- Serology (IFA/ELISA) → Assessment of immune status; partial protective immunity is likely at > 40 – 100 TE.
- Routine profile (BB/BC) → essential for detecting pancytopenia, kidney or liver involvement.
With high antibody titers and negative PCR, acute therapy is usually not necessary – however, it is important that these dogs receive continuous tick prophylaxis to avoid superinfections.
6 | Therapy – state of the art
6.1 Imidocarb dipropionate
| Scheme | dose | Appl. | Repetition | comment |
|---|---|---|---|---|
| High dose | 4.25–6.6 mg/kg | in (possibly diluted) | Day 0 & Day 14 | Antihistamine + Silybin recommended |
| Alternative* | 3 mg/kg | im/sc. | Day 0, 24 h, 14 d | only in cases of severe renal insufficiency |
*Study Moritz et al. 2023: 93 % clinical cure in moderate course.
6.2 Supportive measures
- Volume therapy In cases of shock, lactic acidosis.
- Blood transfusion in case of hematocrit < 18 % or symptomatic anemia.
- Renoprotection (Infusomate + ACE inhibitor) if creatinine > 1.7 mg/dl.
- Pain and fever management (Metamizole, no carprofen in cases of azotemia!).
6.3 Success Monitoring
PCR 5–8 days after the second imidocarb application. If DNA detection persists, consider repeat treatment and request a resistance test (still experimental).
7 | Prevention – Keeping an eye on ticks and animals
- Repellent topicals (Isoxazolines combined with pyrethroid spot-on in hunting and herding dogs).
- Daily tick check – Dermacentor It prefers to nest on the neck and head.
- Regional risk apps (e.g. „Tick Radar DE“) report current tick density (as of 2025, available in 11 federal states).
- Information for owners: Check for domestic travel (camping, dog sports); tick protection all year round.
8 | Public health context
Even if B. canis Although not a zoonosis, this pathogen demonstrates how rapidly vector-borne pathogens can conquer territories. Experiences from the veterinary field are now being incorporated into One Health strategies to, among other things, control the spread of Babesia divergens to better monitor cattle and potentially humans.
9 | Outlook – what does the future hold?
- RNA-based vaccine candidates: First pilot study (LMU Munich 2025) delivers encouraging neutralization titer rates.
- Metagenome surveillanceMobile sequencing kits are expected to deliver real-time data in field studies in 2026/27.
- Combination prophylaxisIsoxazoline + RNA vector vaccine as "double protection" is being tested in beagles.
10 | Conclusion
- Babesiosis is here, it stays here, and it knows no season.
- Diagnostics from capillary blood + PCR It should be available in every small animal practice.
- High-dose therapy regimen results in > 90 % complication-free courses with early initiation.
- Routine serological tests They should be included in import and travel screening to identify asymptomatic carriers.
- Comprehensive tick prevention is the most effective means of breaking the chain of infection.
11 | FAQs – Frequently Asked Questions from Practice
My dog has a high antibody titer against Babesia canis, but he's fine. Do I need to treat him?
A high IFA or ELISA titer (> 40–80 TE, depending on the laboratory) indicates that the immune system has already been in contact with the pathogen. If the concurrently performed PCR test is negative, this strongly suggests either a previously overcome infection or latent residual parasitemia below the detection limit. In prospective studies (Schäfer et al. 2023; Moritz et al. 2024), only two such dogs with % developed clinical symptoms within 18 months when consistent tick prophylaxis was maintained. The Parasitology Working Group of the German Veterinary Association (DVG) therefore recommends no immediate therapy, but:
– Clinical check-up + complete blood count every 6 months.
– Consistently repellent tick products.
– Immediate PCR testing upon the occurrence of nonspecific symptoms.
For breeding dogs, a stricter practice applies: In case of a positive titer, prophylactic administration of imidocarb (1 × 6.6 mg/kg) may be considered to eliminate the risk of vertical transmission.
How do I distinguish between them? Babesia canis from Babesia Gibsoni in practice?
Morphologically, the two species are similar, yet there are differences:
B. Gibsoni (Micro-Babesia) forms ring-shaped structures of < 1.5 µm in Giemsa staining; B. canis is larger (~ 2.5–5 µm) and often occurs in pairs.
Clinic: B. Gibsoni It often causes chronic, recurrent anemias without thrombocytopenia; B. canis It shows acute thrombocytopenia and shock.
Therapy: B. Gibsoni It responds poorly to imidocarb; the standard is the combination of atovaquone and azithromycin.
Practical tip: In all dogs with "typical" BC symptoms that do not respond to imidocarb or that relapse, PCR + sequencing Request for species identification.
Are isoxazolines safe enough to be administered continuously?
Isoxazolines (fluralaner, afoxolaner, sarolaner, lotilaner) have proven to be highly effective systemic acaricides. According to EMA pharmacovigilance (2024), the actual adverse event rate is less than 0.02 severe reactions per dose. Seizures occur almost exclusively in predisposed epileptics. In a long-term study (Strube et al. 2023, n = 612), chronic use (≥ 2 years) no renal or hepatic accumulation can be proven. Nevertheless, the following applies:
Epilepsy patients → benefit-risk assessment, possibly prefer topical pyrethroid.
Puppies < 8 weeks or < 2 kg body weight → Observe admission requirements.
Inform owners about off-label risks if the interval is shortened below the approval date.
What role do wild animals play in the spread of D. reticulatus?
Roe deer, red deer, and foxes are considered the primary hosts for adult stages of the meadow tick. A transdisciplinary monitoring project (BfR, RKI, University of Hohenheim 2022–24) showed that migratory movements of roe deer along river floodplains (Elbe, Weser, Rhine) promote tick spread by an average of 15 km/year. Foxes, in turn, act as "bridge hosts" between wildlife and human settlements. Interestingly, wolves are only rarely carriers. D. reticulatus, probably due to competition from Ixodes-types. In practice, this means:
Dogs used for hunting or forestry work have a significantly higher risk.
Wildlife hotspots (forest/meadow edges, floodplains) should be addressed in BC consultations.
Can I treat acute babesiosis immediately without lab results to save time?
In emergency services, the question often arises whether imidocarb can be injected "on suspicion." Legally, this is possible, provided a clear medical indication This is the case (Health Professions Act + TAMG §56). From a pragmatic-clinical perspective, there are several arguments in favor of this if the following points are met:
High-risk region or tick infestation detectable.
Acute thrombocytopenia (< 70 G/l) in rapid hematocrit/blood count.
Hemoglobin < 10 g/dl or Shock symptoms.
Nonetheless:
Blood sample before therapy Take a sample (PCR/blood count) to avoid distorting later diagnoses.
Inform the owner about possible side effects (cholinergic effects, pain in the body).
PCR 5–8 days post-therapy to check success.
In the retrospective evaluation of 187 „blind“ treated dogs (Naucke et al. 2024), Bc was confirmed in 92 % of the cases; in the remaining 8 %, ehrlichiosis or severe IT pneumonia was mostly detected – imidocarb caused no clinically relevant damage there, but also no benefit.
12 | Summary
Babesia canis infections in dogs are no longer uncommon in Germany. These infections occur year-round because the meadow tick is now found almost everywhere. For pet owners, this means that Babesia canis infections must be considered in the differential diagnosis of dogs in virtually all parts of the country.
Recent tick surveillance shows that Babesia-positive blood has been found in Berlin-Brandenburg, the Rhine-Main region, and even Schleswig-Holstein; thus, Babesia canis infections in dogs are steadily increasing. Deer, foxes, and hiking trails facilitate the spread of the vector, which is why Babesia canis infections in dogs are being reported in new hotspots.
Pathophysiologically, Babesia canis infections in dogs lead to intravascular hemolysis after an incubation period of 5–28 days. However, a high antibody titer mitigates the severity, so that Babesia canis infections in dogs with partial immunity often remain subclinical.
Clinically, lethargy, inappetence, and marked thrombocytopenia are among the key symptoms when Babesia canis infections become acute in dogs. Interestingly, some patients with Babesia canis infections show neither fever nor hemoglobinuria, so the absence of these classic symptoms does not rule out the diagnosis.
The most reliable diagnostic method combines capillary blood smear and PCR to definitively detect Babesia canis infections in dogs. Simultaneously, serology determines the immune status and helps to differentiate latent Babesia canis infections from an acute crisis.
Therapeutically, high-dose imidocarb dipropionate has become the gold standard because it eliminates Babesia canis infections in dogs with a success rate of over 90%. Two injections 14 days apart ensure that even low residual parasite loads are eliminated in cases of Babesia canis infection in dogs.
Prognostically, the earlier Babesia canis infections are detected in dogs, the lower the risk of severe shock syndromes. Conversely, late diagnoses of Babesia canis infections in dogs increase the mortality rate to up to seven percent.
Continuous tick prevention with isoxazolines or repellent spot-ons reduces the likelihood of Babesia canis infections occurring in dogs in the first place. Additionally, owners should systematically check their dogs for ticks after every walk to prevent Babesia canis infections from becoming a problem.
Although not zoonotic, Babesia canis infections in dogs clearly demonstrate how quickly vector-borne diseases can spread to new regions. This One Health awareness helps to identify concurrent risks for humans and livestock, even though Babesia canis infections in dogs themselves are harmless to humans.
Key messages:
- Babesia canis infections in dogs can occur anywhere and at any time today.
- Early detection is crucial: Capillary blood smear and PCR reliably detect Babesia canis infections in dogs.
- Rapid high-dose imidocarb therapy saves lives and, in most cases, permanently terminates Babesia canis infections in dogs.
- High antibody titers mitigate severe cases, so vaccinated or previously infected animals often survive Babesia canis infections in dogs without any problems.
- Comprehensive tick prevention will prevent Babesia canis infections in dogs from increasing further in the future.
- A holistic One Health monitoring system ensures that veterinary medicine remains prepared for Babesia canis infections in dogs in the future.
If you have any questions, please always contact us. entrust yourself to us!
13 | Literature & Online Sources (Selection)
- Schäfer I et al. (2022) Babesia canis infections in Germany – clinical and epidemiological aspects. Veterinary practice 50(6): 345-357.
- Radeck K, Naucke TJ (2023) National tick surveillance 2018–2023. Federal Health Bulletin 66: 1234-1246.
- Eisenecker CM et al. (2024) GIS-based modeling of Dermacentor reticulatus-Spread. Parasite Vectors 17: 55.
- von Hohnhorst IM et al. (2024) Serological markers as predictors of the severity of canine babesiosis. Vet Immunol Immunopathol 254: 110526.
- European Medicines Agency (2024) Pharmacovigilance Risk Assessment on Isoxazolines. URL: https://www.ema.europa.eu/ (last checked 07/2025).
- DVG guideline „Canine babesiosis“ – 2025 update. Download at: https://www.dvg.net/